IFW

DOCKET NO.: C1037.70038US01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Krieg et al.
Serial No.:	10/735,592
Confirmation No.:	2533
Filed:	December 11, 2003
For:	5' CPG NUCLEIC ACIDS AND METHODS OF USE
Examiner:	Nita M. Minnifield
Art Unit:	1645

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 18th day of July, 2006.

Emily E. Zukauskas

Emily E. Zukauskas

MAIL STOP AMENDMENT
Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith are the following documents:

- Information Disclosure Statement
- PTO Form 1449 with cited references
- Copy of International Search Report dated October 12, 2005
- Return Receipt Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 646-8000, Boston, Massachusetts.

A check is not enclosed. If a fee is required, the Commissioner is hereby authorized to charge Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,

By: Helen Lockhart

Helen C. Lockhart, Ph.D., Reg. No.: 39,248
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2206
Telephone: (617) 646-8000

Docket No.: C1037.70038US01
Date: July 18, 2006
xNDDx

DOCKET NO.: C1037.70038US01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Krieg et al.
Serial No.:	10/735,592
Confirmation No.:	2533
Filed:	December 11, 2003
For:	5' CPG NUCLEIC ACIDS AND METHODS OF USE
Examiner:	Nita M. Minnifield
Art Unit:	1645

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 18th day of July, 2006.

Emily E. Zukauskas

Emily E. Zukauskas

MAIL STOP AMENDMENT
Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith are the following documents:

- Information Disclosure Statement
- PTO Form 1449 with cited references
- Copy of International Search Report dated October 12, 2005
- Return Receipt Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 646-8000, Boston, Massachusetts.

A check is not enclosed. If a fee is required, the Commissioner is hereby authorized to charge Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,

By: Helen Lockhart

Helen C. Lockhart, Ph.D., Reg. No.: 39,248
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2206
Telephone: (617) 646-8000

Docket No.: C1037.70038US01
Date: July 18, 2006
xNDDx

DOCKET NO.: C1037.70038US01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Krieg et al.
Serial No.:	10/735,592
Confirmation No.:	2533
Filed:	December 11, 2003
For:	5' CPG NUCLEIC ACIDS AND METHODS OF USE
Examiner:	Nita M. Minnifield
Art Unit:	1645

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 18th day of July, 2006.

Emily E. Zukauskas

Emily E. Zukauskas

MAIL STOP AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

STATEMENT FILED PURSUANT TO THE DUTY OF DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement has been filed before the mailing of a first Office action on the merits in the above-identified case.

No fee or certification is required.

PART II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified PTO/SB/08). The order of presentation of the references should not be construed as an indication of the importance of the references.

The Applicant hereby makes the following additional information of record in the above-identified application.

The Applicant would like to bring to the Examiner's attention the following co-pending applications that may contain subject matter related to this application:

Serial No.	Filing Date	Inventor(s)	Docket No.
10/532,746	04-26-2005	Ahluwalia et al.	*C1037.70035US01
11/179,008	07-08-2005	Hartmann et al.	*C1039.70044US02
11/255,100	10-20-2005	Krieg et al.	*C1037.70059US01
11/301,360	12-09-2005	Bratzler et al.	*C1037.70013US02
11/361,313	02-24-2006	Krieg et al.	*C1037.70060US01
11/368,333	03-03-2006	Lipford et al.	*C1041.70037US01
11/368,334	03-03-2006	Krieg et al.	*C1039.70065US01
11/401,093	04-10-2006	Krieg et al.	*C1037.70062US01
11/411,975	04-26-2006	Uhlmann et al.	*C1041.70045US01

*A copy of this reference is not provided as the Office has waived the requirement under 37 C.F.R. 1.98(a)(2)(iii) for submitting a copy of a cited U.S. patent application if it is scanned to the Image File Wrapper system and is available on Private PAIR.

The Applicant would like to bring to the Examiner's attention the enclosed search report from a corresponding International or Foreign National Application.

Serial No.	Mailing Date	Type(s) of Communication	Docket No.
PCT/US03/39775	**October 12, 2005**	**International Search Report**	**C1037.70038WO00**

PART III: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;

2. The enclosed form PTO-1449 (modified PTO/SB/08) be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;

3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his or her own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.

Respectfully submitted,

By: 

Helen C. Lockhart, Ph.D., Reg. No. 39,248
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2206
Telephone: (617) 646-8000

Docket No.: C1037.70038US01
Date: July 18, 2006
xNDDx
1013073.1

FORM PTO-1449/A and B (modified PTO/SB/08)	APPLICATION NO.: 10/735,592	ATTY. DOCKET NO.: C1037.70038US01
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: December 11, 2003	CONFIRMATION NO.: 2533
	APPLICANT: Krieg et al.	
Sheet 1 of 14	GROUP ART UNIT: 1645	EXAMINER: Nita M. Minnifield

U.S. PATENT DOCUMENTS

Examiner's Initials #	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
	A103	3,906,092		Hilleman et al.	09-16-1975
	A104	5,087,617		Smith	02-11-1992
	A105	5,457,189		Crooke et al.	10-10-1995
	A106	5,475,096		Gold et al.	12-12-1995
	A107	5,514,577		Draper et al.	05-07-1996
	A108	5,576,208		Monia et al.	11-19-1996
	A109	5,576,302		Cook et al.	11-19-1996
	A110	5,582,986		Monia et al.	12-10-1996
	A111	5,663,153		Hutcherson et al.	09-02-1997
	A112	5,684,147		Agrawal et al.	11-04-1997
	A113	5,696,249		Gold et al.	12-09-1997
	A114	5,726,160		McMichael	03-10-1998
	A115	5,843,653		Gold et al.	12-01-1998
	A116	5,955,059		Gilchrest et al.	09-21-1999
	A117	5,968,909		Agrawal et al.	10-19-1999
	A118	5,977,340		Pirotzky et al.	11-02-1999
	A119	5,994,315		Nyce et al.	11-30-1999
	A120	6,025,339		Nyce et al.	02-15-2000
	A121	6,031,086		Switzer	02-29-2000
	A122	6,040,296		Nyce et al.	03-21-2000
	A123	6,090,791		Sato et al.	07-18-2000
	A124	6,121,434		Peyman et al.	09-19-2000
	A125	6,184,369	B1	Rando et al.	02-06-2001
	A126	6,221,882		Macfarlane	04-24-2001
	A127	6,225,292	B1	Raz et al.	05-01-2001
	A128	6,339,630		Macfarlane	06-04-2002
	A129	6,348,312		Peyman et al.	02-19-2002
	A130	6,426,334	B1	Agrawal et al.	07-30-2002
	A131	6,476,000	B1	Agrawal et al.	11-05-2002
	A132	6,479,504		Macfarlane et al.	11-12-2002
	A133	6,498,147	B1	Nerenberg et al.	12-24-2002
	A134	6,503,533	B1	Korba et al.	01-07-2003

EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)	APPLICATION NO.: 10/735,592	ATTY. DOCKET NO.: C1037.70038US01
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: December 11, 2003	CONFIRMATION NO.: 2533
	APPLICANT: Krieg et al.	
Sheet 2 of 14	GROUP ART UNIT: 1645	EXAMINER: Nita M. Minnifield

	A135	6,521,637		Macfarlane	02-18-2003
	A136	6,558,670	B1	Friede et al.	05-06-2003
	A137	6,605,708		Habus et al.	08-12-2003
	A138	6,613,751	B1	Raz et al.	09-02-2003
	A139	6,693,086	B1	Dow et al.	02-17-2004
	A140	6,737,066	B1	Moss	05-18-2004
	A141	6,821,957	B1	Krieg et al.	11-23-2004
	A142	6,835,395	B1	Semple et al.	12-28-2004
	A143	6,943,240		Bauer et al.	09-13-2005
	A144	6,949,520		Hartmann et al.	09-27-2005
	A145	7,001,890		Wagner et al.	02-26-2006
	A146	2001-0021772	A1	Uhlmann et al.	09-13-2001
	A147	2001-0046967	A1	Van Nest et al.	11-29-2001
	A148	2002-0028784	A1	Van Nest et al.	03-07-2002
	A149	2002-0042387	A1	Raz et al.	04-11-2002
	A150	2002-0055477	A1	Van Nest et al.	05-09-2002
	A151	2002-0086839	A1	Raz et al.	07-04-2002
	A152	2002-0098199	A1	Van Nest et al.	07-25-2002
	A153	2002-0102255	A1	Chang	08-01-2002
	A154	2002-0107212	A1	Van Nest et al.	08-08-2002
	A155	2002-0137714	A1	Kandamilla et al.	09-26-2002
	A156	2002-0142977	A1	Raz et al.	10-03-2002
	A157	2002-0142978	A1	Raz et al.	10-03-2002
	A158	2002-0192184	A1	Carpentier et al.	12-19-2002
	A159	2003-0022852	A1	Van Nest et al.	01-30-2003
	A160	2003-0049266	A1	Fearon et al.	03-13-2003
	A161	2003-0059773	A1	Van Nest et al.	03-27-2003
	A162	2003-0060440	A1	Klinman et al.	03-27-2003
	A163	2003-0064064	A1	Dina et al.	04-03-2003
	A164	2003-0078223	A1	Raz et al.	04-24-2003
	A165	2003-0092663	A1	Raz et al.	05-15-2003
	A166	2003-0104044	A1	Semple et al.	06-05-2003
	A167	2003-0119773	A1	Raz et al.	06-26-2003
	A168	2003-0125284	A1	Raz et al.	07-03-2003
	A169	2003-0129251	A1	Van Nest et al.	07-10-2003
	A170	2003-0130217	A1	Raz et al.	07-10-2003

EXAMINER:	DATE CONSIDERED:

[#] EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)	APPLICATION NO.: 10/735,592	ATTY. DOCKET NO.: C1037.70038US01
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: December 11, 2003	CONFIRMATION NO.: 2533
	APPLICANT: Krieg et al.	
Sheet 3 of 14	GROUP ART UNIT: 1645	EXAMINER: Nita M. Minnifield

	A171	2003-0133988	A1	Fearon et al.	07-17-2003
	A172	2003-0143213	A1	Raz et al.	07-31-2003
	A173	2003-0147870	A1	Raz et al.	08-07-2003
	A174	2003-0165478	A1	Sokoll et al.	09-04-2003
	A175	2003-0175731	A1	Fearon et al.	09-18-2003
	A176	2003-0176373	A1	Raz et al.	09-18-2003
	A177	2003-0176389	A1	Raz et al.	09-18-2003
	A178	2003-0199466	A1	Fearon et al.	10-23-2003
	A179	2003-0212026	A1	Krieg et al.	11-13-2003
	A180	2003-0212028	A1	Raz et al.	11-13-2003
	A181	2003-0216340	A1	Van Nest et al.	11-20-2003
	A182	2003-0224010	A1	Davis et al.	12-04-2003
	A183	2003-0225016	A1	Fearon et al.	12-04-2003
	A184	2003-0232780	A1	Carson et al.	12-18-2003
	A185	2003-0232856	A1	Macfarlane	12-18-2003
	A186	2004-0006010	A1	Carson et al.	01-08-2004
	A187	2004-0006034	A1	Raz et al.	01-08-2004
	A188	2004-0009942	A1	Van Nest et al.	01-15-2004
	A189	2004-0013688	A1	Wise et al.	01-22-2004
	A190	2004-0030118	A1	Wagner et al.	02-12-2004
	A191	2004-0038922	A1	Haensler et al.	02-26-2004
	A192	2004-0053880	A1	Krieg	03-18-2004
	A193	2004-0058883	A1	Phillips et al.	03-25-2004
	A194	2004-0067902	A9	Bratzler et al.	04-08-2004
	A195	2004-0067905	A1	Krieg	04-08-2004
	A196	2004-0087534	A1	Krieg et al.	05-06-2004
	A197	2004-0087538	A1	Krieg et al.	05-06-2004
	A198	2004-0092468	A1	Schwartz et al.	05-13-2004
	A199	2004-0092472	A1	Krieg	05-13-2004
	A200	2004-0097719	A1	Agrawal et al.	05-20-2004
	A201	2004-0105872	A1	Klinman et al.	06-03-2004
	A202	2004-0106568	A1	Krieg et al.	06-03-2004
	A203	2004-0115219	A1	Ahn et al.	06-17-2004
	A204	2004-0131628	A1	Bratzler et al.	07-08-2004
	A205	2004-0132677	A1	Fearon et al.	07-08-2004
	A206	2004-0132685	A1	Krieg et al.	07-08-2004

EXAMINER:	DATE CONSIDERED:

[#] EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)	APPLICATION NO.: 10/735,592	ATTY. DOCKET NO.: C1037.70038US01
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: December 11, 2003	CONFIRMATION NO.: 2533
	APPLICANT: Krieg et al.	
Sheet 4 of 14	GROUP ART UNIT: 1645	EXAMINER: Nita M. Minnifield

	A207	2004-0136948	A1	Fearon et al.	07-15-2004
	A208	2004-0142469	A1	Krieg et al.	07-22-2004
	A209	2004-0143112	A1	Krieg et al.	07-22-2004
	A210	2004-0147468	A1	Krieg et al.	07-29-2004
	A211	2004-0152649	A1	Krieg	08-05-2004
	A212	2004-0152656	A1	Krieg et al.	08-05-2004
	A213	2004-0152657	A1	Krieg et al.	08-05-2004
	A214	2004-0162258	A1	Krieg et al.	08-19-2004
	A215	2004-0162262	A1	Krieg et al.	08-19-2004
	A216	2004-0167089	A1	Krieg et al.	08-26-2004
	A217	2004-0171150	A1	Krieg et al.	09-02-2004
	A218	2004-0171571	A1	Krieg et al.	09-02-2004
	A219	2004-0181045	A1	Krieg et al.	09-16-2004
	A220	2004-0198680	A1	Krieg	10-07-2004
	A221	2004-0198688	A1	Krieg et al.	10-07-2004
	A222	2004-0229835	A1	Krieg et al.	11-18-2004
	A223	2004-0234512	A1	Wagner et al.	11-25-2004
	A224	2004-0235770	A1	Davis et al.	11-25-2004
	A225	2004-0235774	A1	Bratzler et al.	11-25-2004
	A226	2004-0235777	A1	Wagner et al.	11-25-2004
	A227	2004-0235778	A1	Wagner et al.	11-25-2004
	A228	2004-0247662	A1	Dow et al.	12-09-2004
	A229	2004-0248837	A1	Raz et al.	12-09-2004
	A230	2004-0266719	A1	McCluskie et al.	12-30-2004
	A231	2005-0004061	A1	Krieg et al.	01-06-2005
	A232	2005-0004062	A1	Krieg et al.	01-06-2005
	A233	2005-0004144	A1	Carson et al.	01-06-2005
	A234	2005-0009774	A1	Krieg et al.	01-13-2005
	A235	2005-0013812	A1	Dow et al.	01-20-2005
	A236	2005-0031638	A1	Dalemans et al.	02-10-2005
	A237	2005-0032734	A1	Davis et al.	02-10-2005
	A238	2005-0032736	A1	Krieg et al.	02-10-2005
	A239	2005-0037403	A1	Krieg et al.	02-17-2005
	A240	2005-0037985	A1	Krieg et al.	02-17-2005
	A241	2005-0043529	A1	Davis et al.	02-24-2005
	A242	2005-0049215	A1	Krieg et al.	03-03-2005

EXAMINER:	DATE CONSIDERED:

[#] EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)	APPLICATION NO.: 10/735,592	ATTY. DOCKET NO.: C1037.70038US01
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: December 11, 2003	CONFIRMATION NO.: 2533
	APPLICANT: Krieg et al.	
Sheet 5 of 14	GROUP ART UNIT: 1645	EXAMINER: Nita M. Minnifield

	A243	2005-0049216	A1	Krieg et al.	03-03-2005
	A244	2005-0054601	A1	Wagner et al.	03-10-2005
	A245	2005-0054602	A1	Krieg et al.	03-10-2005
	A246	2005-0059619	A1	Krieg et al.	03-17-2005
	A247	2005-0059625	A1	Krieg et al.	03-17-2005
	A248	2005-0059626	A1	Van Nest et al.	03-17-2005
	A249	2005-0064401	A1	Olek et al.	03-24-2005
	A250	2005-0070491	A1	Krieg et al.	03-31-2005
	A251	2005-0075302	A1	Hutcherson et al.	04-07-2005
	A252	2005-0100983	A1	Bauer et al.	05-12-2005
	A253	2005-0101554	A1	Krieg et al.	05-12-2005
	A254	2005-0101557	A1	Krieg et al.	05-12-2005
	A255	2005-0119273	A1	Lipford et al.	06-02-2005
	A256	2005-0123523	A1	Krieg et al.	06-09-2005
	A257	2005-0130911	A1	Uhlmann et al.	06-16-2005
	A258	2005-0130918	A1	Agrawal et al.	06-16-2005
	A259	2005-0148537	A1	Krieg et al.	07-07-2005
	A260	2005-0152921	A1	Kim et al.	07-14-2005
	A261	2005-0158336	A1	Diamond et al.	07-21-2005
	A262	2005-0159351	A1	Grate et al.	07-21-2005
	A263	2005-0159375	A1	Srivastava et al.	07-21-2005
	A264	2005-0169888	A1	Hartman et al.	08-04-2005
	A265	2005-0171047	A1	Krieg et al.	08-04-2005
	A266	2005-0176672	A1	Scheule et al.	08-11-2005
	A267	2005-0181422	A1	Bauer et al.	08-18-2005
	A268	2005-0182017	A1	Krieg	08-18-2005
	A269	2005-0191342	A1	Tam et al.	09-01-2005
	A270	2005-0196411	A1	Moss et al.	09-08-2005
	A271	2005-0197314	A1	Krieg et al.	09-08-2005
	A272	2005-0203039	A1	Jeon et al.	09-15-2005
	A273	2005-0209183	A1	Kippenberger et al.	09-22-2005
	A274	2005-0209184	A1	Klinman et al.	09-22-2005
	A275	2005-0214355		Klinman et al.	09-29-2005
	A276	2005-0215500	A1	Krieg et al.	09-29-2005
	A277	2005-0215501	A1	Lipford et al.	09-29-2005
	A278	2005-0233995	A1	Krieg et al.	10-20-2005

EXAMINER:	DATE CONSIDERED:

[#] EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)	APPLICATION NO.: 10/735,592	ATTY. DOCKET NO.: C1037.70038US01
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: December 11, 2003	CONFIRMATION NO.: 2533
	APPLICANT: Krieg et al.	
Sheet 6 of 14	GROUP ART UNIT: 1645	EXAMINER: Nita M. Minnifield

	A279	2005-0233999	A1	Krieg et al.	10-20-2005
	A280	2005-0239732	A1	Krieg et al.	10-27-2005
	A281	2005-0239733	A1	Jurk et al.	10-27-2005
	A282	2005-0239734	A1	Uhlmann et al.	10-27-2005
	A283	2005-0239736	A1	Krieg et al.	10-27-2005
	A284	2005-0245477	A1	Krieg et al.	11-03-2005
	A285	2005-0244379	A1	Krieg et al.	11-03-2005
	A286	2005-0244380	A1	Krieg et al.	11-03-2005
	A287	2005-0250726	A1	Krieg et al.	11-10-2005
	A288	2005-0256073	A1	Lipford et al.	11-17-2005
	A289	2005-0267057	A1	Krieg	12-01-2005
	A290	2005-0267064	A1	Krieg et al.	12-01-2005
	A291	2005-0277604	A1	Krieg et al.	12-15-2005
	A292	2005-0277609	A1	Krieg et al.	12-15-2005
	A293	2006-0003955	A1	Krieg et al.	01-05-2006
	A294	2006-0003962	A1	Ahluwalia et al.	01-05-2006
	A295	2006-0019916	A1	Krieg et al.	01-26-2006
	A296	2006-0019923	A1	Davis et al.	01-26-2006
	A297	2006-0058251	A1	Krieg et al.	03-16-2006
	A298	2006-0089326	A1	Krieg et al.	04-27-2006
	A299	2006-0094683	A1	Krieg et al.	05-04-2006
	A300	2006-0140875	A1	Krieg et al.	06-29-2006

FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
	B48	WO	90/14822	A1	Northwestern University	12-13-1990	
	B49	WO	95/17507	A1	Biognostik Gesellschaft Für Biomolekulare Diagnostik MBH [DE]	06-29-1995	
	B50	WO	96/02555	A1	University of Iowa Research Foundation	02-01-1996	
	B51	WO	96/02560	A1	University of North Carolina at Chapel Hill	02-01-1996	
	B52	WO	96/40162	A1	East Carolina University	12-19-1996	
	B53	WO	98/11211	A2	Hybridon et al.	03-19-1998	
	B54	WO	98/49288	A1	Hybridon Inc.	11-05-1998	
	B55	WO	98/52962	A1	Merck and Co., Inc.	11-26-1998	
	B56	WO	99/33488	A2	SmithKline Beecham Biologicals S.A.	07-08-1999	

EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)	APPLICATION NO.: 10/735,592	ATTY. DOCKET NO.: C1037.70038US01
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: December 11, 2003	CONFIRMATION NO.: 2533
	APPLICANT: Krieg et al.	
Sheet 7 of 14	GROUP ART UNIT: 1645	EXAMINER: Nita M. Minnifield

	B57	WO	99/33868	A2	SmithKline Beecham Biologicals, S.A.	07-08-1999	
	B58	WO	99/56755	A1	University of Iowa Research Foundation	11-11-1999	
	B59	WO	00/06588	A1	University of Iowa Research Foundation	02-10-2000	
	B60	WO	00/15256	A2	Pasteur Merieux Serums Et Vaccins [FR]	03-23-2000	Abstract
	B61	WO	00/23105	A2	SmithKline Beecham Biologicals, S.A.	04-27-2000	
	B62	WO	00/41463	A2	SmithKline Beecham Biologicals, S.A.	07-20-2000	
	B63	WO	00/46365	A1	Virginia Commonwealth University	08-10-2000	
	B64	WO	00/54803	A2	Panacea Pharmaceuticals, LLC.	09-21-2000	
	B65	WO	00/56359	A2	SmithKline Beecham Biologicals, S.A.	09-28-2000	
	B66	WO	00/61151	A2	The Government of the United States of America	10-19-2000	
	B67	WO	00/67787	A2	The Immune Response Corporation	11-16-2000	
	B68	WO	00/75304	A1	Aventis Pasteur [FR]	12-14-2000	Abstract
	B69	WO	01/00231	A2	SmithKline Beecham Biologicals, S.A.	01-04-2001	
	B70	WO	01/00232	A2	SmithKline Beecham Biologicals, S.A.	01-04-2001	
	B71	WO	01/17550	A2	SmithKline Beecham Biologicals, S.A.	03-15-2001	
	B72	WO	01/17551	A2	SmithKline Beecham Biologicals, S.A.	03-15-2001	
	B73	WO	01/54719	A2	SmithKline Beecham Biologicals, S.A.	08-02-2001	
	B74	WO	01/62909	A1	Aventis Pasteur [FR]	08-30-2001	Abstract
	B75	WO	01/93902	A2	Biosynexus Incorporated	12-13-2001	
	B76	WO	02/09748	A1	Yale University	02-07-2002	
	B77	WO	02/28428	A2	Aventis Pasteur [FR]	04-11-2002	Abstract
	B78	WO	02/102307	A2	Ribapharm	12-27-2002	
	B79	WO	03/002065	A2	Chiron Corporation	01-09-2003	
	B80	WO	03/025119	A2	Medarex Inc.	03-27-2003	
	B81	WO	03/026688	A1	Pharmaderm Laboratories, Ltd.	04-03-2003	
	B82	WO	03/035836	A2	Hybridon, Inc.	05-01-2003	
	B83	WO	03/066649	A1	Biomira Inc.	08-14-2003	
	B84	WO	2004/026888	A2	Coley Pharmaceutical GmbH	04-01-2004	
	B85	WO	2004/007743	A2	Coley Pharmaceutical GmbH	01-22-2004	
	B86	WO	2004/094671	A2	Coley Pharmaceutical GmbH	11-04-2004	
	B87	WO	2005/001055	A2	Hybridon Inc.	01-06-2005	
	B88	WO	2005/004910	A2	Intercell Ag	01-20-2005	
	B89	WO	2005/023289	A1	Intellectual Property Consulting Incorporated	03-17-2005	Abstract

EXAMINER:	DATE CONSIDERED:

[#] EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)	APPLICATION NO.: 10/735,592	ATTY. DOCKET NO.: C1037.70038US01
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: December 11, 2003	CONFIRMATION NO.: 2533
	APPLICANT: Krieg et al.	
Sheet 8 of 14	GROUP ART UNIT: 1645	EXAMINER: Nita M. Minnifield

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	C195	[No Author Listed] Antiviral Agents Bulletin. 5(6), 1992.	
	C196	AGRAWAL et al., Pharmacokinetics of oligonucleotides. Ciba Found Symp. 1997;209:60-75; discussion 75-8.	
	C197	AGRAWAL et al., Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration. Biochem Pharmacol. 1995 Aug 8;50(4):571-6.	
	C198	AGRAWAL et al., In vivo pharmacokinetics of phosphorothioate oligonucleotides containing contiguous guanosines. Antisense Nucleic Acid Drug Dev. 1997 Jun;7(3):245-9.	
	C199	AGRAWAL et al., Novel immunomodulatory oligonucleotides prevent development of allergic airway inflammation and airway hyperresponsiveness in asthma. Int Immunopharmacol. 2004 Jan;4(1):127-38.	
	C200	AGRAWAL et al., Antisense therapeutics: is it as simple as complementary base recognition? Mol Med Today. 2000 Feb;6(2):72-81.	
	C201	AGRAWAL et al., Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7595-9.	
	C202	AGRAWAL et al., Medicinal chemistry and therapeutic potential of CpG DNA. Trends Mol Med. 2002 Mar;8(3):114-21.	
	C203	AGRAWAL et al., Pharmacokinetics of antisense oligonucleotides. Clin Pharmacokinet. 1995 Jan;28(1):7-16.	
	C204	AMMERPOHL et al., Complex protein binding to the mouse M-lysozyme gene downstream enhancer involves single-stranded DNA binding. Gene. 1997 Oct 24;200(1-2):75-84.	
	C205	AN et al., Isoforms of the EP3 subtype of human prostaglandin E2 receptor transduce both intracellular calcium and cAMP signals. Biochemistry. 1994 Dec 6;33(48):14496-502.	
	C206	ANDERSON et al., Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. J Clin Invest. 1996 Jun 1;97(11):2672-9.	
	C207	ANITESCU et al., Interleukin-10 functions in vitro and in vivo to inhibit bacterial DNA-induced secretion of interleukin-12. J Interferon Cytokine Res. 1997 Dec;17(12):781-8.	
	C208	BALLAS et al., Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J Immunol. 2001 Nov 1;167(9):4878-86.	
	C209	BOCHNER et al., Advances in mechanisms of allergy. J Allergy Clin Immunol. 2004 May;113(5):868-75.	
	C210	BOHLE et al., Oligodeoxynucleotides containing CpG motifs induce IL-12, IL-18 and IFN-gamma production in cells from allergic individuals and inhibit IgE synthesis in vitro. Eur J Immunol. 1999 Jul;29(7):2344-53.	
	C211	BROIDE et al., Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice. J Immunol. 1998 Dec 15;161(12):7054-62.	
	C212	BROIDE et al., Modulation of asthmatic response by immunostimulatory DNA sequences. Springer Semin Immunopathol. 2000;22(1-2):117-24.	
	C213	BROIDE et al., DNA-Based immunization for asthma. Int Arch Allergy Immunol. 1999 Feb-Apr;118(2-4):453-6.	

EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)	APPLICATION NO.: 10/735,592	ATTY. DOCKET NO.: C1037.70038US01
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: December 11, 2003	CONFIRMATION NO.: 2533
	APPLICANT: Krieg et al.	
Sheet 9 of 14	GROUP ART UNIT: 1645	EXAMINER: Nita M. Minnifield

	C214	CARSON et al., Oligonucleotide adjuvants for T helper 1 (Th1)-specific vaccination. J Exp Med. 1997 Nov 17;186(10):1621-2.	
	C215	CHACE et al., Bacterial DNA-induced NK cell IFN-gamma production is dependent on macrophage secretion of IL-12. Clin Immunol Immunopathol. 1997 Aug;84(2):185-93.	
	C216	CHU et al., CpG oligodeoxynucleotides down-regulate macrophage class II MHC antigen processing. J Immunol. 1999 Aug 1;163(3):1188-94.	
	C217	CROOKE et al., Phosphorothioate Oligonucleotides. Therapeut Apps. 1995;ch5:63-84.	
	C218	CROOKE et al., Progress in antisense oligonucleotide therapeutics. Annu Rev Pharmacol Toxicol. 1996;36:107-29.	
	C219	DALPKE et al., Phosphodiester CpG oligonucleotides as adjuvants: polyguanosine runs enhance cellular uptake and improve immunostimulative activity of phosphodiester CpG oligonucleotides in vitro and in vivo. Immunology. 2002 May;106(1):102-12.	
	C220	FILION et al., Major limitations in the use of cationic liposomes for DNA delivery. Int J Pharmaceut. 1998; 162:159-70.	
	C221	GOMIS et al., Protection of chickens against Escherichia coli infections by DNA containing CpG motifs. Infect Immun. 2003 Feb;71(2):857-63.	
	C222	GROSSMANN et al., Avoiding tolerance against prostatic antigens with subdominant peptide epitopes. J Immunother. 2001 May-Jun;24(3):237-41.	
	C223	GURSEL et al., Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides. J Immunol. 2001 Sep 15;167(6):3324-8.	
	C224	GURSEL et al., Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide. J Leukoc Biol. 2002 May;71(5):813-20. Abstract Only.	
	C225	HARTMANN et al., CpG DNA and LPS induce distinct patterns of activation in human monocytes. Gene Ther. 1999 May;6(5):893-903.	
	C226	HARTMANN et al., Spontaneous and cationic lipid-mediated uptake of antisense oligonucleotides in human monocytes and lymphocytes. J Pharmacol Exp Ther. 1998 May;285(2):920-8.	
	C227	IOANNOU et al., The immunogenicity and protective efficacy of bovine herpesvirus 1 glycoprotein D plus Emulsigen are increased by formulation with CpG oligodeoxynucleotides. J Virol. 2002 Sep;76(18):9002-10.	
	C228	JAIN et al., CpG-oligodeoxynucleotides inhibit airway remodeling in a murine model of chronic asthma. J Allergy Clin Immunol. 2002 Dec;110(6):867-72.	
	C229	JAIN et al., CpG DNA and immunotherapy of allergic airway diseases. Clin Exp Allergy. 2003 Oct;33(10):1330-5.	
	C230	JAIN et al., CpG DNA: immunomodulation and remodelling of the asthmatic airway. Expert Opin Biol Ther. 2004 Sep;4(9):1533-40.	
	C231	KANDIMALLA et al., A dinucleotide motif in oligonucleotides shows potent immunomodulatory activity and overrides species-specific recognition observed with CpG motif. Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14303-8.	
	C232	KANDIMALLA et al., Towards optimal design of second-generation immunomodulatory oligonucleotides. Curr Opin Mol Ther. 2002 Apr;4(2):122-9.	
	C233	KANDIMALLA et al., Divergent synthetic nucleotide motif recognition pattern: design and development of potent immunomodulatory oligodeoxyribonucleotide agents with distinct cytokine induction profiles. Nucleic Acids Res. 2003 May 1;31(9):2393-400.	

EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)	APPLICATION NO.: 10/735,592	ATTY. DOCKET NO.: C1037.70038US01
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: December 11, 2003	CONFIRMATION NO.: 2533
	APPLICANT: Krieg et al.	
Sheet 10 of 14	GROUP ART UNIT: 1645	EXAMINER: Nita M. Minnifield

	C234	KANDIMALLA et al., Effect of chemical modifications of cytosine and guanine in a CpG-motif of oligonucleotides: structure-immunostimulatory activity relationships. Bioorg Med Chem. 2001 Mar;9(3):807-13.	
	C235	KATAOKA et al., Immunotherapeutic potential in guinea-pig tumor model of deoxyribonucleic acid from Mycobacterium bovis BCG complexed with poly-L-lysine and carboxymethylcellulose. Jpn J Med Sci Biol. 1990 Oct;43(5):171-82.	
	C236	KITAGAKI et al., Immunomodulatory effects of CpG oligodeoxynucleotides on established th2 responses. Clin Diagn Lab Immunol. 2002 Nov;9(6):1260-9.	
	C237	KLINE et al., Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J Immunol. 1998 Mar 15;160(6):2555-9.	
	C238	KLINE et al., Treatment of established asthma in a murine model using CpG oligodeoxynucleotides. Am J Physiol Lung Cell Mol Physiol. 2002 Jul;283(1):L170-9.	
	C239	KLINE et al., DNA therapy for asthma. Curr Opin Allergy Clin Immunol. 2002 Feb;2(1):69-73.	
	C240	KLINE et al., Effects of CpG DNA on Th1/Th2 balance in asthma. Curr Top Microbiol Immunol. 2000;247:211-25.	
	C241	KLINE et al., CpG oligodeoxynucleotides do not require TH1 cytokines to prevent eosinophilic airway inflammation in a murine model of asthma. J Allergy Clin Immunol. 1999 Dec;104(6):1258-64.	
	C242	KLINMAN et al., Therapeutic applications of CpG-containing oligodeoxynucleotides. Antisense Nucleic Acid Drug Dev. 1998 Apr;8(2):181-4.	
	C243	KLINMAN et al., Immunotherapeutic applications of CpG-containing oligodeoxynucleotides. Drug News Perspect. 2000 Jun;13(5):289-96.	
	C244	KLINMAN et al., CpG motifs as immune adjuvants. Vaccine. 1999 Jan;17(1):19-25.	
	C245	KRIEG et al., American College of Rheumatology 58th National Scientific Meeting. Minneapolis, Minnesota, October 22, 1994. Abstracts. Arthritis Rheum. 1994 Sep;37(9 Suppl).	
	C246	KRIEG et al., Direct immunologic activities of CpG DNA and implications for gene therapy. J Gene Med. 1999 Jan-Feb;1(1):56-63.	
	C247	KRIEG et al., Applictions of immune stimulatory CpG DNA for antigen-specific and antigen-nonspecific cancer immunotherapy. Eur J Canc. 1999 Oct; 35/Suppl4:S10. Abstract #14.	
	C248	KRIEG et al., Causing a commotion in the blood: immunotherapy progresses from bacteria to bacterial DNA. Immunol Today. 2000 Oct;21(10):521-6.	
	C249	KRIEG et al., Chapter 8: Immune Stimulation by Oligonucleotides. in Antisense Research and Application. Crooke, editor. 1998; 243-62.	
	C250	KRIEG et al., A role for endogenous retroviral sequences in the regulation of lymphocyte activation. J Immunol. 1989 Oct 15;143(8):2448-51.	
	C251	KRIEG et al., P-chirality-dependent immune activation by phosphorothioate CpG oligodeoxynucleotides. Oligonucleotides. 2003;13(6):491-9.	
	C252	KRIEG et al., Chapter 17:Immune stimulation by oligonucleotides. in Antisense Drug Tech. 2001;1394:471-515.	
	C253	KRIEG et al., Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. Biochim Biophys Acta. 1999 Dec 10;1489(1):107-16.	

EXAMINER:	DATE CONSIDERED:

[#] EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)	APPLICATION NO.: 10/735,592	ATTY. DOCKET NO.: C1037.70038US01
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: December 11, 2003	CONFIRMATION NO.: 2533
	APPLICANT: Krieg et al.	
Sheet 11 of 14	GROUP ART UNIT: 1645	EXAMINER: Nita M. Minnifield

	C254	KRIEG et al., The CpG motif: Implications for clinical immunology. BioDrugs. 1998 Nov 1;10(5):341-6.	
	C255	KRIEG et al., Mechanism of action of CpG DNA. Curr Top Microbiol Immunol. 2000;247:1-21.	
	C256	KRIEG et al., CpG DNA: a novel immunomodulator. Trends Microbiol. 1999 Feb;7(2):64-5.	
	C257	KRIEG, Signal transduction induced by immunostimulatory CpG DNA. Springer Semin Immunopathol. 2000;22(1-2):97-105.	
	C258	KRIEG et al., How to exclude immunostimulatory and other nonantisense effects of antisense oligonucleotides. Manual of Antisense. 1999:79-89.	
	C259	KRIEG et al., Unmethylated CpG DNA protects mice from lethal listeria monocytogenes challenge. Vaccines. 1997; 97:77-9.	
	C260	KRIEG et al., Infection. In McGraw Hill Book. 1996: 242-3.	
	C261	KRIEG et al., Lymphocyte activation by CpG dinucleotide motifs in prokaryotic DNA. Trends Microbiol. 1996 Feb;4(2):73-6.	
	C262	KRUG et al., Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol. 2001 Jul;31(7):2154-63.	
	C263	KRUG et al., Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol. 2001 Oct;31(10):3026-37.	
	C264	KURAMOTO et al., Induction of T-cell-mediated immunity against MethA fibrosarcoma by intratumoral injections of a bacillus Calmette-Guerin nucleic acid fraction. Cancer Immunol Immunother. 1992;34(5):283-8.	
	C265	LIU et al., CpG directly induces T-bet expression and inhibits IgG1 and IgE switching in B cells. Nat Immunol. 2003 Jul;4(7):687-93.	
	C266	MacFARLANE et al., Unmethylated CpG-containing oligodeoxynucleotides inhibit apoptosis in WEHI 231 B lymphocytes induced by several agents: evidence for blockade of apoptosis at a distal signalling step. Immunology. 1997 Aug;91(4):586-93.	
	C267	MARSHALL et al., Immunostimulatory sequence DNA linked to the Amb a 1 allergen promotes T(H)1 cytokine expression while downregulating T(H)2 cytokine expression in PBMCs from human patients with ragweed allergy. J Allergy Clin Immunol. 2001 Aug;108(2):191-7.	
	C268	MARTIN-OROZCO et al., Enhancement of antigen-presenting cell surface molecules involved in cognate interactions by immunostimulatory DNA sequences. Int Immunol. 1999 Jul;11(7):1111-8.	
	C269	MESSINA et al., The influence of DNA structure on the in vitro stimulation of murine lymphocytes by natural and synthetic polynucleotide antigens. Cell Immunol. 1993 Mar;147(1):148-57.	
	C270	MUHLHAUSER et al., VEGF165 expressed by a replication-deficient recombinant adenovirus vector induces angiogenesis in vivo. Circ Res. 1995 Dec;77(6):1077-86.	
	C271	OCHIAI et al., Studies on lymphocyte subsets of regional lymph nodes after endoscopic injection of biological response modifiers in gastric cancer patients. Int J Immunotherapy. 1986;11(4):259-65.	
	C272	PARRONCHI et al., Phosphorothioate oligodeoxynucleotides promote the in vitro development of human allergen-specific CD4+ T cells into Th1 effectors. J Immunol. 1999 Dec 1;163(11):5946-53.	
	C273	PISETSKY et al., Immunological properties of bacterial DNA. Ann N Y Acad Sci. 1995 Nov 27;772:152-63.	
	C274	PISETSKY et al., Influence of backbone chemistry on immune activation by synthetic oligonucleotides. Biochem Pharmacol. 1999 Dec 15;58(12):1981-8.	

EXAMINER:	DATE CONSIDERED:

[#] EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)	APPLICATION NO.: 10/735,592	ATTY. DOCKET NO.: C1037.70038US01
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: December 11, 2003	CONFIRMATION NO.: 2533
	APPLICANT: Krieg et al.	
Sheet 12 of 14	GROUP ART UNIT: 1645	EXAMINER: Nita M. Minnifield

	C275	PISETSKY et al., Immune activation by bacterial DNA: a new genetic code. Immunity. 1996 Oct;5(4):303-10.	
	C276	PISETSKY et al., The influence of base sequence on the immunological properties of defined oligonucleotides. Immunopharmacology. 1998 Nov;40(3):199-208.	
	C277	POLANCZYK et al., Immunostimulatory effects of DNA and CpG motifs. Cent Eur J of Immunol. 2000;25(3):160-6.	
	C278	RANKIN et al., CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved. Antisense Nucleic Acid Drug Dev. 2001 Oct;11(5):333-40.	
	C279	RANKIN et al., CpG-containing oligodeoxynucleotides augment and switch the immune responses of cattle to bovine herpesvirus-1 glycoprotein D. Vaccine. 2002 Jul 26;20(23-24):3014-22.	
	C280	RAZ et al., Potential role of immunostimulatory DNA sequences (ISS) in genetic immunization and autoimmunity. ACR Poster Session C: Cytokines and Inflammatory Mediators. 1996 Oct 20; Abstract Number 615.	
	C281	REDECKE et al., Cutting edge: activation of Toll-like receptor 2 induces a Th2 immune response and promotes experimental asthma. J Immunol. 2004 Mar 1;172(5):2739-43.	
	C282	ROTHENFUSSER et al., Recent advances in immunostimulatory CpG oligonucleotides. Curr Opin Mol Ther. 2003 Apr;5(2):98-106.	
	C283	SANDLER et al., CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma. Cancer Res. 2003 Jan 15;63(2):394-9.	
	C284	SANDRASAGRA et al., Discovery and development of respirable antisense therapeutics for asthma. Antisense Nucleic Acid Drug Dev. 2002 Jun;12(3):177-81.	
	C285	SANDS et al., Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate. Mol Pharmacol. 1994 May;45(5):932-43.	
	C286	SINGH et al., Cationic microparticles are an effective delivery system for immune stimulatory CpG DNA. Pharm Res. 2001 Oct;18(10):1476-9.	
	C287	SPARWASSER et al., Bacterial DNA causes septic shock. Nature. 1997 Mar 27;386(6623):336-7.	
	C288	SPARWASSER et al., Immunostimulatory CpG-oligodeoxynucleotides cause extramedullary murine hemopoiesis. J Immunol. 1999 Feb 15;162(4):2368-74.	
	C289	SPIEGELBERG et al., DNA-based approaches to the treatment of allergies. Curr Opin Mol Ther. 2002 Feb;4(1):64-71.	
	C290	STEIN et al., Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. Antisense Res Dev. 1994 Summer;4(2):67-9.	
	C291	STEIN et al., Physicochemical properties of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res. 1988 Apr 25;16(8):3209-21.	
	C292	STEIN et al., Non-antisense effects of oligodeoxynucleotides. Antisense Technology. 1997; ch11: 241-64.	
	C293	STEIN et al., Antisense oligonucleotides as therapeutic agents--is the bullet really magical? Science. 1993 Aug 20;261(5124):1004-12.	

EXAMINER:	DATE CONSIDERED:

[#] EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)	APPLICATION NO.: 10/735,592	ATTY. DOCKET NO.: C1037.70038US01
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: December 11, 2003	CONFIRMATION NO.: 2533
	APPLICANT: Krieg et al.	
Sheet 13 of 14	GROUP ART UNIT: 1645	EXAMINER: Nita M. Minnifield

	C294	STUNZ et al., Inhibitory oligonucleotides specifically block effects of stimulatory CpG oligonucleotides in B cells. Eur J Immunol. 2002 May;32(5):1212-22.	
	C295	SUR et al., Long term prevention of allergic lung inflammation in a mouse model of asthma by CpG oligodeoxynucleotides. J Immunol. 1999 May 15;162(10):6284-93.	
	C296	TANAKA et al., An antisense oligonucleotide complementary to a sequence in I gamma 2b increases gamma 2b germline transcripts, stimulates B cell DNA synthesis, and inhibits immunoglobulin secretion. J Exp Med. 1992 Feb 1;175(2):597-607.	
	C297	UHLMANN et al., Recent advances in the development of immunostimulatory oligonucleotides. Curr Opin Drug Discov Devel. 2003 Mar;6(2):204-17.	
	C298	VAN UDEN et al., Immunostimulatory DNA and applications to allergic disease. J Allergy Clin Immunol. 1999 Nov;104(5):902-10.	
	C299	VERTHELYI et al., Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates. Clin Immunol. 2003 Oct;109(1):64-71.	
	C300	VERTHELYI et al., Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs. J Immunol. 2001 Feb 15;166(4):2372-7.	
	C301	VOLLMER et al., Highly immunostimulatory CpG-free oligodeoxynucleotides for activation of human leukocytes. Antisense Nucleic Acid Drug Dev. 2002 Jun;12(3):165-75.	
	C302	VOLLMER et al., Immunopharmacology of CpG oligodeoxynucleotides and ribavirin. Antimicrob Agents Chemother. 2004 Jun;48(6):2314-7.	
	C303	VOLLMER et al., Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol. 2004 Jan;34(1):251-62.	
	C304	VOLLMER et al., Modulation of CpG oligodeoxynucleotide-mediated immune stimulation by locked nucleic acid (LNA). Oligonucleotides. 2004 Spring;14(1):23-31.	
	C305	WANG et al., Synergy between CpG- or non-CpG DNA and specific antigen for B cell activation. Int Immunol. 2003 Feb;15(2):223-31.	
	C306	WHITESELL et al., Stability, clearance, and disposition of intraventricularly administered oligodeoxynucleotides: implications for therapeutic application within the central nervous system. Proc Natl Acad Sci U S A. 1993 May 15;90(10):4665-9.	
	C307	YAMAMOTO et al., [Commemorative lecture of receiving Imamura Memorial Prize. II. Mode of action of oligonucleotide fraction extracted from Mycobacterium bovis BCG] Kekkaku. 1994 Sep;69(9):571-4.	Abstract
	C308	YAMAMOTO et al., Synthetic oligonucleotides with certain palindromes stimulate interferon production of human peripheral blood lymphocytes in vitro. Jpn J Cancer Res. 1994 Aug;85(8):775-9.	
	C309	YI et al., CpG DNA rescue of murine B lymphoma cells from anti-IgM-induced growth arrest and programmed cell death is associated with increased expression of c-myc and bcl-xL. J Immunol. 1996 Dec 1;157(11):4918-25.	
	C310	YU et al., Accessible 5'-end of CpG-containing phosphorothioate oligodeoxynucleotides is essential for immunostimulatory activity. Bioorg Med Chem Lett. 2000 Dec 4;10(23):2585-8.	
	C311	ZHAO et al., Pattern and kinetics of cytokine production following administration of phosphorothioate oligonucleotides in mice. Antisense Nucleic Acid Drug Dev. 1997 Oct;7(5):495-502.	

EXAMINER:	DATE CONSIDERED:

[#] EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**				APPLICATION NO.: 10/735,592	ATTY. DOCKET NO.: C1037.70038US01
				FILING DATE: December 11, 2003	CONFIRMATION NO.: 2533
				APPLICANT: Krieg et al.	
Sheet	14	of	14	GROUP ART UNIT: 1645	EXAMINER: Nita M. Minnifield

	C312	ZHAO et al., Modulation of oligonucleotide-induced immune stimulation by cyclodextrin analogs. Biochem Pharmacol. 1996 Nov 22;52(10):1537-44.	
	C313	ZHAO et al., Effect of different chemically modified oligodeoxynucleotides on immune stimulation. Biochem Pharmacol. 1996 Jan 26;51(2):173-82.	

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.